-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Serum -X- _ B-Intervention
procalcitonin -X- _ I-Intervention
levels -X- _ I-Intervention
have -X- _ O
been -X- _ O
used -X- _ O
as -X- _ O
a -X- _ O
biomarker -X- _ O
of -X- _ O
invasive -X- _ O
bacterial -X- _ O
infection -X- _ O
and -X- _ O
recently -X- _ O
have -X- _ O
been -X- _ O
advocated -X- _ O
to -X- _ O
guide -X- _ O
antibiotic -X- _ O
therapy -X- _ O
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
chronic -X- _ I-Patient
obstructive -X- _ I-Patient
pulmonary -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
COPD -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
However -X- _ O
, -X- _ O
rigorous -X- _ O
studies -X- _ O
correlating -X- _ O
procalcitonin -X- _ B-Intervention
levels -X- _ I-Intervention
with -X- _ O
microbiologic -X- _ O
data -X- _ O
are -X- _ O
lacking. -X- _ O
Acute -X- _ B-Patient
exacerbations -X- _ I-Patient
of -X- _ I-Patient
COPD -X- _ I-Patient
( -X- _ I-Patient
AECOPD -X- _ I-Patient
) -X- _ I-Patient
have -X- _ O
been -X- _ O
linked -X- _ O
to -X- _ O
viral -X- _ O
and -X- _ O
bacterial -X- _ O
infection -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
noninfectious -X- _ O
causes. -X- _ O
Therefore -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
procalcitonin -X- _ B-Intervention
as -X- _ O
a -X- _ O
predictor -X- _ O
of -X- _ O
viral -X- _ O
versus -X- _ O
bacterial -X- _ O
infection -X- _ O
in -X- _ O
patients -X- _ B-Patient
hospitalized -X- _ I-Patient
with -X- _ I-Patient
AECOPD -X- _ I-Patient
with -X- _ I-Patient
and -X- _ I-Patient
without -X- _ I-Patient
evidence -X- _ I-Patient
of -X- _ I-Patient
pneumonia. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
Adults -X- _ O
hospitalized -X- _ O
during -X- _ O
the -X- _ O
winter -X- _ O
with -X- _ O
symptoms -X- _ O
consistent -X- _ O
with -X- _ O
AECOPD -X- _ B-Patient
underwent -X- _ O
extensive -X- _ O
testing -X- _ O
for -X- _ O
viral -X- _ O
, -X- _ O
bacterial -X- _ O
, -X- _ O
and -X- _ O
atypical -X- _ O
pathogens. -X- _ O
Serum -X- _ B-Intervention
procalcitonin -X- _ I-Intervention
levels -X- _ I-Intervention
were -X- _ O
measured -X- _ O
on -X- _ O
day -X- _ O
1 -X- _ O
( -X- _ O
admission -X- _ O
) -X- _ O
, -X- _ O
day -X- _ O
2 -X- _ O
, -X- _ O
and -X- _ O
at -X- _ O
one -X- _ O
month. -X- _ O
Clinical -X- _ O
and -X- _ O
laboratory -X- _ O
features -X- _ O
of -X- _ O
subjects -X- _ O
with -X- _ O
viral -X- _ O
and -X- _ O
bacterial -X- _ O
diagnoses -X- _ O
were -X- _ O
compared. -X- _ O
RESULTS -X- _ O
: -X- _ O
In -X- _ O
total -X- _ O
, -X- _ O
224 -X- _ B-Outcome
subjects -X- _ I-Outcome
with -X- _ I-Outcome
COPD -X- _ I-Outcome
were -X- _ I-Outcome
admitted -X- _ I-Outcome
for -X- _ I-Outcome
240 -X- _ I-Outcome
respiratory -X- _ I-Outcome
illnesses. -X- _ I-Outcome
Of -X- _ I-Outcome
these -X- _ I-Outcome
, -X- _ I-Outcome
56 -X- _ I-Outcome
had -X- _ I-Outcome
pneumonia -X- _ I-Outcome
and -X- _ I-Outcome
184 -X- _ I-Outcome
had -X- _ I-Outcome
AECOPD -X- _ I-Outcome
alone. -X- _ I-Outcome
A -X- _ I-Outcome
microbiologic -X- _ I-Outcome
diagnosis -X- _ I-Outcome
was -X- _ I-Outcome
made -X- _ I-Outcome
in -X- _ I-Outcome
76 -X- _ I-Outcome
( -X- _ I-Outcome
56 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
134 -X- _ I-Outcome
illnesses -X- _ I-Outcome
with -X- _ I-Outcome
reliable -X- _ I-Outcome
bacteriology -X- _ I-Outcome
( -X- _ I-Outcome
26 -X- _ I-Outcome
viral -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
29 -X- _ I-Outcome
bacterial -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
21 -X- _ I-Outcome
mixed -X- _ I-Outcome
viral -X- _ I-Outcome
bacterial -X- _ I-Outcome
infection -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Mean -X- _ I-Outcome
procalcitonin -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
pneumonia -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
AECOPD. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
discrimination -X- _ I-Outcome
between -X- _ I-Outcome
viral -X- _ I-Outcome
and -X- _ I-Outcome
bacterial -X- _ I-Outcome
infection -X- _ I-Outcome
using -X- _ I-Outcome
a -X- _ I-Outcome
0.25 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
threshold -X- _ I-Outcome
for -X- _ I-Outcome
bacterial -X- _ I-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
AECOPD -X- _ I-Outcome
was -X- _ I-Outcome
poor. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
Procalcitonin -X- _ B-Intervention
is -X- _ O
useful -X- _ B-Outcome
in -X- _ I-Outcome
COPD -X- _ I-Outcome
patients -X- _ I-Outcome
for -X- _ I-Outcome
alerting -X- _ I-Outcome
clinicians -X- _ I-Outcome
to -X- _ I-Outcome
invasive -X- _ I-Outcome
bacterial -X- _ I-Outcome
infections -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
pneumonia -X- _ I-Outcome
but -X- _ I-Outcome
it -X- _ I-Outcome
does -X- _ I-Outcome
not -X- _ I-Outcome
distinguish -X- _ I-Outcome
bacterial -X- _ I-Outcome
from -X- _ I-Outcome
viral -X- _ I-Outcome
and -X- _ I-Outcome
noninfectious -X- _ I-Outcome
causes -X- _ I-Outcome
of -X- _ I-Outcome
AECOPD -X- _ I-Outcome
. -X- _ O

